#1 Clinical Trials Search in Europe

Jnj-81241459

A new clinical trial is underway to assess the effectiveness and safety of JNJ-81241459, a potential breakthrough medication for individuals suffering from moderate to severe plaque psoriasis. This Phase 2b study aims to compare different doses of the drug against a placebo, offering hope for improved treatment options for those affected by this chronic skin condition.

Table of Contents

What is JNJ-81241459?

JNJ-81241459 is a potential new medicine currently being studied for the treatment of moderate to severe plaque psoriasis. It is undergoing a Phase 2b clinical trial to evaluate its effectiveness and safety[1]. This drug is being developed by Johnson & Johnson Enterprise Innovation Inc. and is administered orally in the form of tablets[1].

Target Condition: Plaque Psoriasis

Plaque psoriasis is a chronic autoimmune condition that affects the skin. It causes rapid buildup of skin cells, resulting in scaly, itchy, and inflamed patches on the skin. The condition can range from mild to severe, and in moderate to severe cases, it can significantly impact a person’s quality of life[1].

Clinical Trial Details

The ongoing clinical trial for JNJ-81241459 is designed to evaluate the drug’s efficacy and safety in treating moderate to severe plaque psoriasis. Here are some key details about the study:

  • Study Type: This is a Phase 2b trial, which means it’s testing the drug’s effectiveness and determining the optimal dosage[1].
  • Study Design: The trial is multicenter (conducted at multiple research sites), randomized (participants are randomly assigned to different groups), double-blind (neither the participants nor the researchers know who is receiving the actual drug or placebo), and placebo-controlled (some participants receive an inactive substance for comparison)[1].
  • Main Objective: To evaluate the efficacy of JNJ-81241459 compared with placebo in participants with moderate to severe plaque psoriasis[1].
  • Primary Endpoint: The main measure of success for this trial is achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) at Week 12 of treatment[1]. PASI is a tool used to measure the severity and extent of psoriasis.

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Here are some of the key inclusion and exclusion criteria:

Inclusion Criteria:

  • Age: 18 years or older[1]
  • Diagnosed with plaque psoriasis[1]
  • Total Body Surface Area (BSA) affected by psoriasis: 10% or more[1]
  • Total Psoriasis Area and Severity Index (PASI) score: 12 or higher[1]
  • Investigator’s Global Assessment (IGA) score: 3 or higher[1]

Exclusion Criteria:

  • Having non-plaque forms of psoriasis (e.g., erythrodermic, guttate, or pustular)[1]
  • Current drug-induced psoriasis[1]
  • Severe, progressive, or uncontrolled medical conditions[1]
  • Current diagnosis or history of Inflammatory Bowel Disease (IBD)[1]
  • Known allergies or hypersensitivity to JNJ-81241459 or its components[1]

Drug Information

JNJ-81241459 is being tested in different dosages during this clinical trial:

  • The drug is administered orally in tablet form[1].
  • Different dosages are being tested, including 50mg and 200mg tablets[1].
  • The treatment period in this study lasts for 12 weeks[1].
  • Some participants will receive a placebo (an inactive substance) for comparison[1].

Potential Benefits

While the effectiveness of JNJ-81241459 is still being studied, the goal of this treatment is to provide relief for patients with moderate to severe plaque psoriasis. If successful, it could offer several potential benefits:

  • Reduction in psoriasis symptoms, such as skin inflammation, scaling, and itching
  • Improvement in the appearance of psoriasis plaques
  • Better quality of life for patients with moderate to severe plaque psoriasis
  • A new oral treatment option, which may be more convenient for some patients compared to other forms of psoriasis treatments

It’s important to note that as this drug is still in the clinical trial phase, its full benefits and potential side effects are not yet fully known. Patients interested in this treatment should consult with their healthcare provider and consider participating in clinical trials if eligible.

Aspect Details
Drug Name JNJ-81241459
Condition Treated Moderate to Severe Plaque Psoriasis
Trial Phase Phase 2b
Administration Oral tablets
Primary Endpoint PASI 75 at Week 12
Key Inclusion Criteria Age ≥18, Plaque Psoriasis diagnosis, BSA ≥10%, PASI ≥12, IGA ≥3
Key Exclusion Criteria Non-plaque psoriasis, drug-induced psoriasis, severe medical conditions, IBD, allergies to JNJ-81241459

FAQ

  • What is JNJ-81241459? JNJ-81241459 is a new drug being tested for the treatment of moderate to severe plaque psoriasis. It is currently in Phase 2b clinical trials to evaluate its effectiveness and safety.
  • Who can participate in this clinical trial? Participants must be at least 18 years old, have a diagnosis of plaque psoriasis, and meet specific criteria related to the severity of their condition, including having at least 10% of their body surface area affected and certain scores on psoriasis assessment scales.
  • How long does the trial last? The primary endpoint of the study is measured at Week 12, suggesting that the initial treatment period lasts for 12 weeks.
  • What is the main goal of this clinical trial? The main objective is to evaluate the efficacy of JNJ-81241459 compared to a placebo in patients with moderate to severe plaque psoriasis.
  • How is the medication administered? JNJ-81241459 is administered orally in the form of tablets. The trial compares different doses of the active drug against placebo tablets.

Ongoing Clinical Trials on Jnj-81241459

  • Study on the Effects of JNJ-81241459 for Patients with Moderate to Severe Psoriasis

    Not recruiting

    2 1 1
    Investigated drugs:
    France Germany Poland Spain

Glossary

  • Plaque Psoriasis: A common form of psoriasis characterized by raised, red patches covered with a silvery white buildup of dead skin cells or scales, typically on the knees, elbows, scalp, and lower back.
  • Phase 2b: A stage in clinical trials that focuses on determining the effectiveness of a drug and evaluating its side effects. It usually involves a larger group of patients than earlier phases.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect. It is used as a control in clinical trials to compare the effects of the active drug.
  • BSA: Body Surface Area, a measure used to determine the extent of psoriasis on a person's body.
  • PASI: Psoriasis Area and Severity Index, a tool used to measure the severity and extent of psoriasis.
  • IGA: Investigator's Global Assessment, a scale used to evaluate the overall severity of psoriasis.
  • PASI 75: A 75% improvement in the Psoriasis Area and Severity Index score, which is the primary endpoint of this study at Week 12.
  • Efficacy: The ability of a drug to produce the desired therapeutic effect.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-jnj-81241459-for-patients-with-moderate-to-severe-psoriasis/